RESUMO
We report the case of a cord blood haematopoietic stem cell transplant recipient who was vaccinated for Yellow Fever (YF) 7 days before initiating chemotherapy and had persistent YF antibodies more than 3 years after vaccination. Since the stem cell donor was never exposed to wild YF or to the YF vaccine, and our patient was not exposed to YF or revaccinated, this finding strongly suggests the persistence of recipient immunity. We briefly discuss potential consequences of incomplete elimination of recipient's leukocytes following existing haematopoietic cancer treatments.
Assuntos
Anticorpos Antivirais/sangue , Transplante de Células-Tronco de Sangue do Cordão Umbilical , Vacina contra Febre Amarela/imunologia , Vírus da Febre Amarela/imunologia , Adulto , Humanos , Terapia de Imunossupressão , Leucemia Mieloide Aguda/tratamento farmacológico , Leucemia Mieloide Aguda/terapia , MasculinoRESUMO
Disseminated infection by Fusarium is a rare, frequently lethal condition in severely immunocompromised patients, including bone marrow transplant recipients. However, autologous bone marrow transplant recipients are not expected to be at high risk to develop fusariosis. We report a rare case of lethal disseminated Fusarium infection in an autologous bone marrow transplant recipient during pre-engraftment phase.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Transplante de Medula Óssea/efeitos adversos , Fusariose/patologia , Linfoma Folicular/cirurgia , Fusariose/diagnóstico , Hospedeiro Imunocomprometido , Transplante AutólogoRESUMO
Disseminated infection by Fusarium is a rare, frequently lethal condition in severely immunocompromised patients, including bone marrow transplant recipients. However, autologous bone marrow transplant recipients are not expected to be at high risk to develop fusariosis. We report a rare case of lethal disseminated Fusarium infection in an autologous bone marrow transplant recipient during pre-engraftment phase.